Literature DB >> 1673424

Disposition of the cephalosporin cefepime in normal and renally impaired subjects.

R H Barbhaiya1, C A Knupp, S T Forgue, G R Matzke, C E Halstenson, J A Opsahl, K A Pittman.   

Abstract

The metabolism and disposition of an iv-administered, 1000 mg (100 microCi) single dose of the 14C-labeled cephalosporin cefepime was studied in healthy and renally impaired male volunteers. The 14C-label was located in the methyl group of the N-methyl pyrrolidine (NMP) moiety at the 3'-position of cefepime. Concentrations of cefepime and its metabolites were determined in plasma and urine as a function of time after drug administration. Cefepime comprised 95 and 76% of the total plasma radioactivity in subjects with normal and impaired renal functions, respectively. The elimination half-life of cefepime was 2 hr in normal volunteers and increased to 4 and 12 hr in subjects with moderate and severe renal impairment, respectively. Steady-state volume of distribution was about 18 liters and was independent of the degree of renal impairment. Cefepime was primarily excreted unchanged in the urine of normal subjects, as 87.9% of the total recovered radioactivity. The major cefepime metabolites, NMP N-oxide, the 7-epimer of cefepime and NMP, constituted 6.8, 2.5, and less than 1% of the total radioactivity excreted in urine, respectively. As the severity of renal impairment increased, the proportion of radioactivity recovered in urine as cefepime decreased and that of NMP-N-oxide increased. Our results indicate that cefepime undergoes minimal metabolism and is excreted primarily as unchanged drug in urine in humans with normal kidney functions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673424

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

1.  Pitfalls in cefepime titration from human plasma: plasma- and temperature-related drug degradation in vitro.

Authors:  Denis Bugnon; Eric Giannoni; Paul Majcherczyk; Michel P Glauser; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Effects of age and gender on pharmacokinetics of cefepime.

Authors:  R H Barbhaiya; C A Knupp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

3.  Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R H Barbhaiya; C A Knupp; M Pfeffer; D Zaccardelli; G M Dukes; W Mattern; K A Pittman; L J Hak
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

4.  Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.

Authors:  M D Reed; T S Yamashita; C K Knupp; J M Veazey; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

5.  Disposition kinetics, bioavailability and renal clearance of cefepime in calves.

Authors:  M M Ismail
Journal:  Vet Res Commun       Date:  2005-01       Impact factor: 2.459

6.  Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves.

Authors:  Y G Pawar; S K Sharma
Journal:  Vet Res Commun       Date:  2007-07-03       Impact factor: 2.459

Review 7.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

8.  Prospective monitoring of cefepime in intensive care unit adult patients.

Authors:  Thomas M Chapuis; Eric Giannoni; Paul A Majcherczyk; René Chioléro; Marie-Denise Schaller; Mette M Berger; Saskia Bolay; Laurent A Décosterd; Denis Bugnon; Philippe Moreillon
Journal:  Crit Care       Date:  2010-04-01       Impact factor: 9.097

9.  Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.

Authors:  Vincent H Tam; Peggy S McKinnon; Ronda L Akins; George L Drusano; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Lack of pharmacokinetic interaction between cefepime and amikacin in humans.

Authors:  R H Barbhaiya; C A Knupp; M Pfeffer; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.